BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
BioNxt Solutions (BNXTF) has received acceptance of its first national level patent filing from the Eurasian Patent Organization (EAPO). The patent, which previously received a positive international examination report from the European Patent Office in September 2024, covers sublingual delivery of anticancer drugs for treating autoimmune neurodegenerative diseases.
The patent notably includes BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for multiple sclerosis treatment. The EAPO protection extends across eight member states: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan. The company is also pursuing patent protection in Australia, Canada, New Zealand, USA, and Japan to support commercialization opportunities for its pipeline of sublingual products targeting various autoimmune diseases.
BioNxt Solutions (BNXTF) ha ottenuto l'accettazione della sua prima domanda di brevetto a livello nazionale dall'Organizzazione dei Brevetti Eurasiatica (EAPO). Il brevetto, che aveva già ricevuto un rapporto di esame internazionale positivo dall'Ufficio Brevetti Europeo a settembre 2024, riguarda la somministrazione sublinguale di farmaci anticancro per il trattamento delle malattie neurodegenerative autoimmuni.
Il brevetto include in particolare il prodotto principale di BioNxt, BNT23001, una formulazione sublinguale in film sottile di Cladribina per il trattamento della sclerosi multipla. La protezione EAPO si estende a otto stati membri: Armenia, Azerbaigian, Bielorussia, Kazakistan, Kirghizistan, Russia, Tagikistan e Turkmenistan. L'azienda sta inoltre perseguendo la protezione brevettuale in Australia, Canada, Nuova Zelanda, USA e Giappone per supportare le opportunità di commercializzazione della sua gamma di prodotti sublinguali destinati a diverse malattie autoimmuni.
BioNxt Solutions (BNXTF) ha recibido la aceptación de su primera solicitud de patente a nivel nacional por parte de la Organización Euroasiática de Patentes (EAPO). La patente, que previamente recibió un informe positivo de examen internacional de la Oficina Europea de Patentes en septiembre de 2024, cubre la administración sublingual de fármacos anticancerígenos para el tratamiento de enfermedades neurodegenerativas autoinmunes.
La patente incluye especialmente el producto principal de BioNxt, BNT23001, una formulación en película delgada sublingual de Cladribina para el tratamiento de la esclerosis múltiple. La protección de la EAPO se extiende a ocho estados miembros: Armenia, Azerbaiyán, Bielorrusia, Kazajistán, Kirguistán, Rusia, Tayikistán y Turkmenistán. La compañía también está buscando protección de patente en Australia, Canadá, Nueva Zelanda, EE. UU. y Japón para apoyar las oportunidades de comercialización de su cartera de productos sublinguales dirigidos a diversas enfermedades autoinmunes.
BioNxt Solutions (BNXTF)는 유라시아 특허기구(EAPO)로부터 첫 국가 수준 특허 출원이 승인되었습니다. 이 특허는 2024년 9월 유럽 특허청으로부터 긍정적인 국제 심사 보고서를 받은 바 있으며, 자가면역 신경퇴행성 질환 치료를 위한 항암제의 설하 투여를 다루고 있습니다.
특히 이 특허에는 다발성 경화증 치료를 위한 클라드리빈 설하 박막 제형인 BioNxt의 주력 제품 BNT23001이 포함되어 있습니다. EAPO 보호는 아르메니아, 아제르바이잔, 벨라루스, 카자흐스탄, 키르기스스탄, 러시아, 타지키스탄, 투르크메니스탄 등 8개 회원국에 걸쳐 적용됩니다. 회사는 또한 호주, 캐나다, 뉴질랜드, 미국, 일본에서도 특허 보호를 추진하여 다양한 자가면역 질환을 대상으로 한 설하 제품 파이프라인의 상업화 기회를 지원하고 있습니다.
BioNxt Solutions (BNXTF) a obtenu l'acceptation de son premier dépôt de brevet au niveau national auprès de l'Organisation Eurasienne des Brevets (EAPO). Le brevet, qui avait déjà reçu un rapport d'examen international positif de l'Office Européen des Brevets en septembre 2024, porte sur l'administration sublinguale de médicaments anticancéreux pour le traitement des maladies neurodégénératives auto-immunes.
Le brevet inclut notamment le produit phare de BioNxt, BNT23001, une formulation en film mince sublingual de Cladribine pour le traitement de la sclérose en plaques. La protection de l'EAPO s'étend à huit États membres : Arménie, Azerbaïdjan, Biélorussie, Kazakhstan, Kirghizistan, Russie, Tadjikistan et Turkménistan. La société cherche également à obtenir une protection par brevet en Australie, au Canada, en Nouvelle-Zélande, aux États-Unis et au Japon afin de soutenir les opportunités de commercialisation de sa gamme de produits sublinguaux ciblant diverses maladies auto-immunes.
BioNxt Solutions (BNXTF) hat die Annahme seiner ersten nationalen Patentanmeldung von der Eurasischen Patentorganisation (EAPO) erhalten. Das Patent, das im September 2024 bereits einen positiven internationalen Prüfbericht vom Europäischen Patentamt erhalten hatte, betrifft die sublinguale Verabreichung von Krebsmedikamenten zur Behandlung von autoimmunen neurodegenerativen Erkrankungen.
Das Patent umfasst insbesondere BioNxts Hauptprodukt, BNT23001, eine sublinguale Dünnfilmformulierung von Cladribin zur Behandlung von Multipler Sklerose. Der EAPO-Schutz erstreckt sich über acht Mitgliedstaaten: Armenien, Aserbaidschan, Belarus, Kasachstan, Kirgisistan, Russland, Tadschikistan und Turkmenistan. Das Unternehmen strebt außerdem Patentschutz in Australien, Kanada, Neuseeland, den USA und Japan an, um die Kommerzialisierungsmöglichkeiten seiner Pipeline sublingualer Produkte für verschiedene Autoimmunerkrankungen zu unterstützen.
- Patent claims confirmed for novelty, inventive step, and industrial applicability by EAPO
- Patent protection secured across eight Eurasian countries through single application process
- Expansion of global patent protection in progress across major markets including US, Canada, Japan
- None.
VANCOUVER, BC / ACCESS Newswire / May 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that its first national level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the Company's core patent claims, namely: novelty, inventive step, and industrial applicability.
BioNxt's flagship patent filing, which received a positive international examination report from the European Patent Office, reported September 9, 2024, is a comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS).
The EAPO covers Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan. These countries are the members of the Eurasian Patent Convention (EAPC), which provides a single, harmonized patent application process and regulator for the region. The EAPO grants Eurasian patents that are valid in all eight member states.
BioNxt continues to advance the nationalization phase of the patent protection process at the European Patent Office and Eurasian Patent Organization, as well as with independent filing nations, such as Australia (AU), Canada (CA), New Zealand (NZ), USA (US), and Japan (JP). Securing nation-level patents around the globe will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
What patent protection did BioNxt Solutions (BNXTF) receive from EAPO in May 2025?
Which countries are covered by BioNxt's EAPO patent approval?
What is BioNxt's (BNXTF) lead product BNT23001?
Which additional countries is BioNxt pursuing patent protection in?
What autoimmune diseases does BioNxt's sublingual product pipeline target?
